Botulinum toxin therapy has emerged as a pivotal treatment in the management of spasticity, a debilitating neuromuscular condition characterised by increased muscle tone and hyperactive reflexes. By ...

Antibody administration following saline or BTX administration at the beginning of the treatment. Anti-IGF1R antibody treatment is denoted as IGF1R and control IgG antibody treatment as control IgG.

PHILADELPHIA, PA - Elan Pharmaceuticals announced today that it is investigating the potential use of MYOBLOC-3/8 (Botulinum Toxin Type B) Injectable Solution in a variety of spasticity, pain and ...

In a comprehensive research study, scientists have uncovered a previously unknown mechanism explaining how neurons survive botulinum neurotoxin type A (BoNT/A) exposure, despite the toxin's powerful ...

PHOENIX -- Botulinum toxin injections offered relief from sialorrhea, or excessive saliva production, in patients with amyotrophic lateral sclerosis (ALS), according to a small study. The ...

Please provide your email address to receive an email when new articles are posted on . Botulinum toxin A significantly improved tear breakup time, tear meniscus height and Schirmer test score.

The use of toxin botulinum-A is one of the most rapidly growing areas in cosmetic dermatology. There is always news about this incredible substance. There are new indications, new techniques, and new ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Gigagen Inc., a subsidiary of Grifols SA, has been awarded a contract by the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop a recombinant polyclonal antibody therapy ...

A new study has highlighted the increase in practitioners administering botulinum toxin in the recent years. This increase highlights the growing concern surrounding unregulated cosmetic practice in ...